Challenges in the development of glaucoma neuroprotection therapy

Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people worldwide. Currently available therapies for this disease only attempt to reduce intraocular pressure, the major risk factor, without addressing the associated optic neuropathy and retinopathy. Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. Unfortunately, many challenges hinder this effort, including an incomplete understanding of the mechanism of pathogenesis, leading to uncertain therapeutic targets and confounded by not yet validated preclinical models. Most importantly, with slow disease progression and a less than ideal endpoint measurement method, clinical trials are necessarily large, lengthy, expensive and, to many, prohibitive. No easy solution is available to overcome these challenges. Increased commitment to basic mechanistic research is an essential foundation for dealing with this problem. Innovations in clinical trials with novel surrogate endpoints, nontraditional study designs and the use of surrogate diseases might shorten the study time, reduce the patient sample size and consequently lower the budgetary hurdle for the development of new therapies.     

Prevalence of diabetes in glaucoma.

Oral glucose 75 g was given to 352 patients with chronic glaucoma, acute glaucoma, or ocular hypertension and 73 patients without glaucoma. The proportion of patients with shallow anterior chambers who showed an abnormal response was significantly greater than that in patients with deep anterior chambers and in the control group (p less than 0.005). The probability of developing an abnormal response to oral glucose tests increased as the depth of the anterior chamber decreased; these two variables showed a significant negative linear correlation (r = -0.79, p less than 0.001). The high prevalence of autonomic dysfunction in patients with shallow anterior chambers and glaucoma may explain this association. Because of this, acute glaucoma should be regarded as a symptom of diabetes.     

Safe and effective methylphenidate therapy in a pediatric patient with glaucoma

Stimulant medications used as first-line treatment in attention deficit hyperactivity disorder (ADHD) are contraindicated in patients with glaucoma. We present the first reported case of using methylphenidate therapy to safely and effectively treat ADHD in a pediatric patient with glaucoma.     

Trabecular meshwork cells are a valuable resource for cellular therapy of glaucoma

Trabecular meshwork (TM) contains a subset of adult stem cells or progenitors that can be differentiated into corneal endothelial cells, adipocytes and chondrocytes, but not osteocytes or keratocytes. Accordingly, these progenitors can be utilized as a cell‐based therapy to prevent blindness caused by glaucoma, corneal endothelial dysfunction and other diseases in general. In this review, we review in vitro expansion techniques for TM progenitors, discuss their phenotypic properties, and highlight their potential clinical applications in various ophthalmic diseases.     

Error propagation in E. coli protein synthesis

A new approach to the error catastrophe theory, proposed by Leslie Orgel, is presented here. Our model is a development of previous models, but differs in several respects: the overall activity is assumed to be dependent on the error level, the effect of errors in the translating system, giving rise to additional errors in the succeeding generation of products, is explicitly included as a special term in our model, and scavenging enzymes are assumed to break down and eliminate products with a loose structure. Their efficiency is dependent on the error level. The model also takes into account the dilution of incorrect ribosomes and enzymes, and is described by a time-dependence in terms of ribosome/enzyme generations. The model and the contribution to the time development are discussed in the light of experiments on E. coli treated with streptomycin.     

Congenital glaucoma due to dominant goniodysgenesis. A new concept of the heredity of glaucoma

Three typical pedigrees with hereditary glaucoma are presented, in which dominant goniodysgenesis is shown to be the actual genetic trait. Because of a marked variation in the expressivity of dysgenesis, the symptoms of the genetic malformation (elevated intraocular pressure and subsequent glaucoma) may appear early or late in life. Therefore, there is no justification in letting the patient's age at the onset of the symptoms decide the classification or the mode of inheritance of the glaucoma (infantile, juvenile, simple), when the common etiologic factor is a dominant dysgenic trait. Consequently, the term "congenital glaucoma" is inadequate and even misleading for glaucoma caused by an inborn malformation, but which may be manifested only after several years or even decades. Instead a new term "dysgenic glaucoma" is suggested as the logical term that also indicates the etiology.